CHMP Backs Novo Nordisk’s Semaglutide for MASH, Opening Door to EU Approval
As reported on MedicalXpress, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for several therapies this
American Liver Foundation
American Liver Foundation
“We are focused on improving patient lives, increasing public awareness of liver disease, advancing liver transplantation and funding cutting-edge liver disease research – we’re working every day to help save lives. As the largest organization focused on all liver diseases, ALF provides trusted support, resources and education while advocating for public policy change and increased government funding for liver disease research on Capitol Hill. ALF serves as a beacon for the 100 million Americans affected by liver disease.”
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Liver Disease
Pemvidutide Shows Sustained Weight Loss and Liver Improvement in Extended MASH Trial Data
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH),
My Journey With MASH
I’m Nella, and this is part of my journey with Metabolic dysfunction-associated steatohepatitis (MASH). I was diagnosed with MASH in early 2024, after being
Eccogene Launches MOSAIC Trial to Test Dual Mechanisms Against Metabolic Liver Disease
Eccogene, a clinical-stage biopharmaceutical company, has announced enrollment of the first patient in MOSAIC, a Phase 2a clinical trial investigating two novel oral small molecules
FDA Approves First AI Tool to Advance MASH Drug Development
As reported by Healio, the U.S. Food and Drug Administration (FDA) has officially qualified AIM-MASH AI Assist, marking a milestone as the first artificial intelligence
Lean Patients With MASLD Face Higher Risk of Poor Outcomes and Mortality
Key Insight: As reported by Healio, metabolic dysfunction-associated steatotic liver disease (MASLD) is not exclusive to individuals with obesity. New research presented at The Liver
